Patients with intermediate to high risk prostate cancer on biopsy are eligible for government‐funded PSMA PET/CT (primary staging) and restaging of patients with recurrent prostate cancer (PSA persistence/biochemical recurrence). This evidence concerns the gene FOLH1 and prostate carcinoma.